Intravenous Infusions is trading 5.80% down at GHS 0.65, with no confirmed company-specific announcement or event identified for September 8, 2026.
- Recent coverage likewise described the decline as unexplained.
- The previously reported 17.31% Zagadat Capital stake was disclosed in May and is not a new catalyst.
- Broader U.S. markets are modestly weaker, but available evidence does not establish a direct connection.